Senti Bio Announces Additional $11.5 Million of Financing
– Approximately $10 million additional investment in private placement equity financing – – $1.5 million from CIRM grant first announced...
Year: 2025
AEON Biopharma, Inc. Announces Pricing of Approximately $20.0 Million Underwritten Public Offering
IRVINE, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (NYSE: AEON) (the “Company”), a clinical-stage biopharmaceutical company focused...
AAMI Updates Materials Compatibility Guidance for EO, Other Modalities
Document Updated for the First Time Since 2017Arlington, Virginia, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Whether a material is compatible...
Achieve Life Sciences to Host Meetings During the J.P. Morgan Healthcare Conference Week
SEATTLE and VANCOUVER, British Columbia, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical...
Quoin Pharmaceuticals Announces Additional Positive Interim Data from Ongoing Open-Label Netherton Syndrome Clinical Study
Highly Positive Clinical Data on Completion of Testing for First Subject Dosed Twice Daily with QRX003 in Open-Label StudyDemonstrated Clinical...
NAYA Biosciences Announces Development of NY-500, a Novel AI-Optimized PD-1 x VEGF Bifunctional Antibody
• PD-1 x VEGF antibodies show potential to surpass checkpoint inhibitors as standard-of-care in multiple oncology indications • NAYA aiming...
Outset Medical Announces $169 Million Private Placement Financing From Leading Mutual Funds and Healthcare Institutional Investors
Secures New Debt Financing of up to $125M Maturing in 2030 with Plans to Retire $200M in Prior Debt Reports Unaudited...
Dyadic Provides Business Update; Dyadic to Attend the 43rd Annual J.P. Morgan Healthcare Conference
JUPITER, Fla., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (Nasdaq: DYAI),...
LB Pharmaceuticals Announces Presentation at the 43rd Annual J.P. Mogan Healthcare Conference
NEW YORK, Jan. 06, 2025 (GLOBE NEWSWIRE) -- LB Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing novel therapies for the...
Ascendis Pharma to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
COPENHAGEN, Denmark, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that company executives will participate...
NeuroOne® Announces Change of Virtual Investor Webinar to Friday, January 10, 2024
Company to Provide Overview of Business Model and Expected Revenue Acceleration in Fiscal Year 2025 EDEN PRAIRIE, Minn., Jan. 06,...
Rakovina Therapeutics Announces Receipt of AI-Derived Drug Candidates and Advancement to Preclinical Validation
VANCOUVER, British Columbia, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV), a biopharmaceutical company focused on the...
Kailera Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference
BOSTON and SAN DIEGO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on advancing...
Profound Medical to Present at the 43rd Annual J.P. Morgan Healthcare Conference
TORONTO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device...
Clearmind Medicine Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination Treatment
Vancouver, Canada, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a...
VITAS® Healthcare Receives the 2024 DAISY Health Equity Award
MIAMI, Jan. 06, 2025 (GLOBE NEWSWIRE) -- The American Association for Men in Nursing (AAMN) has selected VITAS Healthcare as...
Organovo Announces Appointment of Norman Staskey as Chief Financial Officer
SAN DIEGO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing...
Jasper Therapeutics to Host Webinar to Present Preliminary Data from the BEACON Study of Briquilimab in Chronic Spontaneous Urticaria on January 8, 2025
Webinar to be held Wednesday, January 8, 2025, at 8am ESTREDWOOD CITY, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Jasper...
Intra-Cellular Therapies to Present at the 43rd Annual J.P. Morgan Healthcare Conference
BEDMINSTER, N.J., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development...
Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Acceptance and Priority Review of NDA for CUTX-101 for Treatment of Menkes Disease
Priority review granted for CUTX-101 with PDUFA target action date set for June 30, 2025 Cyprium is eligible to receive...